
Trump's Tariff Threat, Retail Earnings Ahead of Black Friday, Amgen Tumbles on Weight-Loss Drug Data 11/26/24
Squawk on the Street
00:00
Amgen's Weight Loss Drug Woes
This chapter examines Amgen's declining stock performance linked to concerns over its experimental weight loss drug and its mixed results in trials. It also discusses the broader market implications of the Biden administration's efforts to expand access to obesity treatments and the volatility in futures trading.
Transcript
Play full episode